Market access

Relief Therapeutics Appoints David McCullough as Head of US Market Access

Relief Therapeutics Holding SA / Keyword(s): People

August 17, 2022 / 07:00 CET/CEST
Publication of an ad hoc announcement pursuant to Art. 53LR
The issuer is solely responsible for the content of this announcement.

Relief Therapeutics Appoints David McCullough as Head of US Market Access

Experienced market access leader of Bolster Relief business operations in the United States

Geneva, Switzerland, August 17, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients with therapeutic benefits for serious diseases with high unmet need, today announced the appointment of David McCullough as Senior Director and Head of US Market Access, from August 22n/a. In this newly created role, reporting to Anthony Kim, Senior Vice President and Head of U.S. Business Operations, Mr. McCullough will lead Relief’s market access strategy and operations to ensure timely and effective at Relief products for patients in the United States.

“David’s appointment as Head of US Market Access marks an important milestone for Relief as we have now completed hiring the US commercial team and are moving closer to patient access to treatments for diseases with unmet medical needs,” Mr. Kim said. “As we continue to grow, David’s more than 20 years of deep business experience working with payers, physicians and specialty pharmacies to help ensure access for patients and their families will be invaluable. With the expertise and relationships forged during his tenures at Mirum Pharmaceuticals, Inc., Novartis Gene Therapies, Spark Therapeutics and other companies, we look forward to leveraging his vast knowledge of market access in view of the US launch of PKU GOLIKE in October 2022.®. With the continued commercialization of Relief products on the horizon, David is a welcome addition to our commercial leadership team.

“Relief’s mission to develop a strong therapeutic portfolio for rare and ultra-rare diseases synergistically aligns with my desire to increase patient access to rare disease treatment options,” added McCullough. . “I look forward to contributing to the commercial sales of PKU GOLIKE® and additional products in the Relief pipeline.

Prior to joining Relief, Mr. McCullough served as National Account Executive (Account Payer) at Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of rare diseases, where he was responsible for the development of the company’s Medicaid launch strategy and support for the expansion of key market access policies. Previously, he held several positions of increasing responsibility at Novartis Gene Therapies (formerly AveXis), most recently as Director of National Accounts, where he was responsible for the successful negotiation of several value-based agreements and 10 Medicaid policies. of state. Previously, he worked as a patient access liaison at Spark Therapeutics, supporting the launch of a first-of-its-kind gene therapy in the area of ​​inherited retinal diseases and also helped establish services for patients and market access operations. Prior to Spark Therapeutics, Mr. McCullough was Associate Director, Patient Services Southeast at Shire. Earlier in his career, Mr. McCullough held numerous market access and commercial operations positions at various biotechnology and pharmaceutical companies, including an Institutional Specialty Manager at MedImmune and a Territory Manager at Abbott Laboratories.

Mr. McCullough holds a BA in Speech/Public Relations from McNeese State University, a BS in Ministry and Theology from St. Louis Christian College, and served four years in the United States Coast Guard.


Relief is a commercial-stage Swiss biopharmaceutical company focused on the identification, development and commercialization of novel patent-protected products for the treatment of rare metabolic, dermatological and pulmonary diseases with a portfolio of clinical and marketed assets that address unmet patient needs. Relief has entered into a collaboration and license agreement with Acer Therapeutics for the development and worldwide commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including UCD and maple syrup urinary disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief’s 2021 acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH have provided Relief with a diverse pipeline of commercialized and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and listed in the United States on the OTCQB under the symbols RLFTF and RLFTY. For more information, visit and follow Relief on LinkedIn.

Jack Weinstein
Financial Director and Treasurer
[email protected]

Rx Communications Group
Michael Miller
[email protected]

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements regarding RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including the risks discussed in RELIEF THERAPEUTICS Holding SA’s filings with SIX and the United States Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Additional Features:

Case: Ad-hoc version

End of privileged information